Use of nanoparticles coated with red blood cell membranes to enable blood transfusion
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10434070-B2
Publication Date
2019-10-08
Expiration Date
Abstract
The present invention relates to methods, combinations and pharmaceutical compositions for supplying a blood source from a donor source with a mis-matched blood type, or potentially a mis-matched blood type, to a recipient, using, inter alia, an effective amount of a nanoparticle comprising a) an inner core comprising a non-cellular material, and b) an outer surface comprising a cellular membrane derived from a red blood cell, the cellular membrane of the nanoparticle comprising a blood type antigen that exists on the red blood cell from the donor source, but is missing or potentially missing on red blood cells of the recipient.
Core Innovation
The invention relates to supplying a blood source to a recipient when the recipient blood type is unknown before receiving the blood source that potentially has a mis-matched blood type, or when the recipient blood type is known and is a mis-match to the blood type of the blood source. The approach supplies a blood source comprising red blood cells from a donor source to a recipient in need of the supplied blood source, and supplies an effective amount of a nanoparticle to the recipient before, during, or after supplying the blood source.
The nanoparticle comprises an inner core comprising a non-cellular material and an outer surface comprising a cellular membrane derived from a red blood cell. The cellular membrane of the nanoparticle comprises a blood type antigen that exists on the red blood cell from the donor source, but is missing or potentially missing on red blood cells of the recipient.
The nanoparticle is configured to present donor red blood cell blood type antigens on the recipient side to address immunologic reaction and hemolysis associated with blood type mismatch. The disclosure further characterizes the membrane-derived blood type antigen by blood group systems, including major blood group systems and minor/rare blood group systems, where the blood type antigens are missing or potentially missing on red blood cells of the recipient.
Claims Coverage
The patent includes two independent claims covering a method and a combination, with three inventive features centered on donor red blood cell blood sources, unknown or mismatched recipient blood type, and a nanoparticle with a red-blood-cell-derived membrane bearing a donor blood type antigen.
Nanoparticle with non-cellular inner core and donor RBC membrane bearing missing or potentially missing blood type antigen
The nanoparticle comprises an inner core comprising a non-cellular material and an outer surface comprising a cellular membrane derived from a red blood cell, wherein the cellular membrane comprises a blood type antigen that exists on the red blood cell from the donor source, but is missing or potentially missing on red blood cells of the recipient.
Method supplying donor red blood cell blood source with nanoparticle when recipient blood type is unknown or mis-matched
A method for supplying a blood source to a recipient comprising supplying a blood source comprising red blood cells from a donor source to a recipient in need thereof, where the recipient blood type is unknown before receiving the blood source that potentially has a mis-matched blood type, or the recipient blood type is known and is a mis-match to the blood type of the blood source, and supplying an effective amount of the nanoparticle before, during, or after supplying the blood source to the recipient.
Combination of nanoparticle and donor red blood cell blood source with unknown or mismatched recipient blood type
A combination for supplying a blood source to a recipient comprising an effective amount of a nanoparticle and an effective amount of a blood source comprising red blood cells from a donor source, wherein the recipient blood type is unknown before receiving the blood source that potentially has a mis-matched blood type, or the recipient blood type is known and is a mis-match to the blood type of the blood source, and the effective amount of the nanoparticle is configured to be supplied to the recipient before, during, or after the blood source is supplied to the recipient.
The inventive features combine administration of a nanoparticle presenting donor blood type antigens via a red-blood-cell-derived membrane with delivery of a donor red blood cell blood source in situations of unknown or mismatched recipient blood type.
Stated Advantages
Reducing or preventing immunologic reactions against the donor red blood cells.
Reducing or preventing hemolysis associated with blood type mismatch.
Documented Applications
Supplying a blood source when the recipient blood type is unknown, including cases where recipient blood type cannot be practically or impossibly determined before providing a blood source that may have a mismatched blood type.
Supplying a blood source when the recipient blood type is known and is mis-matched to the blood type of the blood source.
Interested in licensing this patent?